Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Cancer. 2019 Oct 4;126(1):76–85. doi: 10.1002/cncr.32506

Figure 2. Outcomes in patients with metastatic melanoma treated with PD-1 monotherapy.

Figure 2.

A) Overall survival for the entire cohort (dashed lines indicate 95% CI). B) Overall survival stratified by baseline NLR. C) Time to treatment failure (dashed lines indicate 95% CI). D) Time to treatment failure stratified by baseline NLR.